Payment overview · 2025
General Payments
$3,898.99
47 reported records · 17 companies
Healthcare provider profile · identity verified
Ramy S Doss, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · PHOENIX, AZ · NPI 1629032487
Verified facts
What the public records show
CMS Open Payments records show Ramy S Doss, MD received $3,898.99 in general payments during 2025 across 47 reported records.
BIOTRONIK INC. accounted for 75.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $2,949.58 | 75.7% | 23 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$382.53 | 9.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $109.70 | 2.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $93.94 | 2.4% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $44.77 | 1.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $44.01 | 1.1% | 2 | 2025 |
| AltaThera Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $39.45 | 1.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.26 | 1.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.99 | 0.7% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.13 | 0.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $27.10 | 0.7% | 1 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $24.79 | 0.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.09 | 0.6% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $21.82 | 0.6% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.18 | 0.5% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $15.60 | 0.4% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $10.05 | 0.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,913.03 | 41 |
| Travel and Lodging | $1,798.46 | 5 |
| Education | $187.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ADVISA DR MRI SURESCAN Normalized: advisa dr mri surescan |
Device | Medtronic, Inc. | $192.23 | 4 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $190.30 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $93.94 | 1 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $44.01 | 2 | 2025 |
Source payment records
|
|||||
| Sotalol Hydrochloride Normalized: sotalol hydrochloride |
Drug | AltaThera Pharmaceuticals LLC | $39.45 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $38.26 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $28.99 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $10.05 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
92 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
307 | 87 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 695 | 211 |
| Metoprolol Succinate | Metoprolol Succinate | 485 | 164 |
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 120 |
| Ezetimibe | Ezetimibe | 336 | 104 |
| Eliquis | Apixaban | 307 | 87 |
| Nebivolol Hcl | Nebivolol Hcl | 298 | 103 |
| Lisinopril | Lisinopril | 256 | 91 |
| Losartan Potassium | Losartan Potassium | 248 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 236 | 82 |
| Furosemide | Furosemide | 191 | 85 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 62 |
| Repatha Sureclick | Evolocumab | 141 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 49 |
| Nifedipine Er | Nifedipine | 118 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 98 | 30 |
| Entresto | Sacubitril/Valsartan | 92 | 27 |
| Valsartan | Valsartan | 89 | 25 |
| Candesartan Cilexetil | Candesartan Cilexetil | 88 | 27 |
| Carvedilol | Carvedilol | 86 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 78 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 78 | 29 |
| Vascepa | Icosapent Ethyl | 73 | 19 |
| Chlorthalidone | Chlorthalidone | 65 | 39 |
| Spironolactone | Spironolactone | 58 | 20 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 41 | 11 |
| Clonidine Hcl | Clonidine Hcl | 40 | 14 |
| Potassium Chloride | Potassium Chloride | 40 | 13 |
| Repatha Pushtronex | Evolocumab | 39 | 13 |
| Irbesartan | Irbesartan | 37 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | suppressed |
| Sotalol | Sotalol Hcl | 35 | suppressed |
| Ranolazine Er | Ranolazine | 34 | 13 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Dofetilide | Dofetilide | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 27 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 24 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 23 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Livalo | Pitavastatin Calcium | 21 | suppressed |
| Praluent Pen | Alirocumab | 21 | suppressed |
| Repatha Syringe | Evolocumab | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Camzyos | Mavacamten | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Verquvo | Vericiguat | 12 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,898.99 · 47 records | BIOTRONIK INC. | ADVISA DR MRI SURESCAN, AMVUTTRA, CARDIVA VASCADE MVP VVCS 6-12F, Fintepla, GLASSIA, General - Vascular Intervention, IMCIVREE, LEQVIO, MICRA, NEXLETOL, Nayzilam, Ohtuvayre, RHYTHM EXPRESS, Restrata Wound Matrix, Sotalol Hydrochloride, VYNDAQEL | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error